Lasse Melvaer Giil1,2, Øivind Midttun3, Helga Refsum4,5, Arve Ulvik3, Rajiv Advani6, A David Smith5, Per Magne Ueland2,7. 1. Department of Internal Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway. 2. Department of Clinical Science, University of Bergen, Norway. 3. Bevital AS, Norway. 4. Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Norway. 5. OPTIMA, Department of Pharmacology, University of Oxford, UK. 6. Department of Clinical Medicine, University of Bergen, Norway. 7. Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway.
Abstract
BACKGROUND: Metabolites of tryptophan, produced via the kynurenine pathway (kynurenines), have been linked to Alzheimer's disease (AD) in small cohorts with conflicting results. OBJECTIVE: To compare differences in plasma kynurenine levels between AD and controls and identify potential associations with cognition. METHODS: The study included 65 histopathologically-confirmed AD patients and 65 cognitively-screened controls from the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort. Cognition was assessed using the Cambridge Cognitive Examination (CamCog). Tryptophan, kynurenines, neopterin, and vitamin B6 forms were measured in plasma by liquid chromatography-tandem mass spectrometry. Non-parametric statistics, logistic regression and standardized robust regressions were applied with a false discovery rate of 0.05. RESULTS: Tryptophan, xanthurenic acid, 3-hydroxyanthranilic acid, and quinolinic acid were lower in AD (Odds ratios (ORs) 0.24 -0.47; p-values <0.001 -0.01). Pyridoxal 5'phosphate did not differ between AD and controls. Kynurenine, anthranilic acid, quinolinic acid, and markers of immune activation (neopterin, kynurenine/tryptophan ratio, and the PAr index (Pyridoxic acid/(Pyridoxal 5'phosphate + Pyridoxal)) increased with age (β 0.31 -0.51; p-values <0.001 -0.006). Xanthurenic acid decreased with age (β: -0.42, p < 0.001). Elderly AD patients with high quinolinic acid performed worse on the CamCog test, indicated by a significant age*quinolinic acid interaction (β 0.21, p < 0.001). CONCLUSION: Plasma concentrations of several kynurenines were lower in patients with AD compared to controls. Low xanthurenic acid occurred in both AD and with aging. Inflammation-related markers were associated with age, but not AD. However, elevated QA was associated with poor cognition in older AD patients.
BACKGROUND: Metabolites of tryptophan, produced via the kynurenine pathway (kynurenines), have been linked to Alzheimer's disease (AD) in small cohorts with conflicting results. OBJECTIVE: To compare differences in plasma kynurenine levels between AD and controls and identify potential associations with cognition. METHODS: The study included 65 histopathologically-confirmed ADpatients and 65 cognitively-screened controls from the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort. Cognition was assessed using the Cambridge Cognitive Examination (CamCog). Tryptophan, kynurenines, neopterin, and vitamin B6 forms were measured in plasma by liquid chromatography-tandem mass spectrometry. Non-parametric statistics, logistic regression and standardized robust regressions were applied with a false discovery rate of 0.05. RESULTS:Tryptophan, xanthurenic acid, 3-hydroxyanthranilic acid, and quinolinic acid were lower in AD (Odds ratios (ORs) 0.24 -0.47; p-values <0.001 -0.01). Pyridoxal 5'phosphate did not differ between AD and controls. Kynurenine, anthranilic acid, quinolinic acid, and markers of immune activation (neopterin, kynurenine/tryptophan ratio, and the PAr index (Pyridoxic acid/(Pyridoxal 5'phosphate + Pyridoxal)) increased with age (β 0.31 -0.51; p-values <0.001 -0.006). Xanthurenic acid decreased with age (β: -0.42, p < 0.001). Elderly ADpatients with high quinolinic acid performed worse on the CamCog test, indicated by a significant age*quinolinic acid interaction (β 0.21, p < 0.001). CONCLUSION: Plasma concentrations of several kynurenines were lower in patients with AD compared to controls. Low xanthurenic acid occurred in both AD and with aging. Inflammation-related markers were associated with age, but not AD. However, elevated QA was associated with poor cognition in older ADpatients.
Authors: Michael Y Bai; David B Lovejoy; Gilles J Guillemin; Rouba Kozak; Trevor W Stone; Maju Mathew Koola Journal: Complex Psychiatry Date: 2021-02-08
Authors: Pratishtha Chatterjee; Kathryn Goozee; Chai K Lim; Ian James; Kaikai Shen; Kelly R Jacobs; Hamid R Sohrabi; Tejal Shah; Prita R Asih; Preeti Dave; Candice ManYan; Kevin Taddei; David B Lovejoy; Roger Chung; Gilles J Guillemin; Ralph N Martins Journal: Sci Rep Date: 2018-05-22 Impact factor: 4.379
Authors: Marta González-Sánchez; Javier Jiménez; Arantzazu Narváez; Desiree Antequera; Sara Llamas-Velasco; Alejandro Herrero-San Martín; Jose Antonio Molina Arjona; Adolfo López de Munain; Alberto Lleó Bisa; M-Pilar Marco; Montserrat Rodríguez-Núñez; David Andrés Pérez-Martínez; Alberto Villarejo-Galende; Fernando Bartolome; Elena Domínguez; Eva Carro Journal: Biomolecules Date: 2020-04-08
Authors: Bernadett Tuka; Aliz Nyári; Edina Katalin Cseh; Tamás Körtési; Dániel Veréb; Ferenc Tömösi; Gábor Kecskeméti; Tamás Janáky; János Tajti; László Vécsei Journal: J Headache Pain Date: 2021-06-25 Impact factor: 7.277
Authors: Knut Biber; Anindya Bhattacharya; Brian M Campbell; Justin R Piro; Michael Rohe; Roland G W Staal; Robert V Talanian; Thomas Möller Journal: Front Pharmacol Date: 2019-08-23 Impact factor: 5.810